Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611024 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
A Phase 1 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 1
- Development phase
- 316
- Enrollment target
NCT02611024 is a Phase 1 study that has completed, run by PharmaMar. The registered enrollment target is 316 participants.
The verdict
NCT02611024, a Phase 1 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 316 participants
- Enrollment target
Study Summary
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
Interventions
- DRUG Irinotecan
- DRUG Lurbinectedin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2016-05-06 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02611024
The ClinicalTrials.gov registry entry for NCT02611024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT02611024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02611024 about?
NCT02611024 is a clinical study titled "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors". Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
What is the current status of trial NCT02611024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 316 participants. The study started on 2016-05-06. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT02611024?
The interventions under investigation include: Irinotecan (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT02611024?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.